Aviragen Therapeutics (AVIR) Misses Q2 EPS by 3c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.44), $0.03 worse than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• X Financial (XYF) Tops Q2 EPS by 438c
• Azenta names board member as interim CEO after Marotta resigns
• AEG and Archer plan first downtown Los Angeles vertiport at L.A. LIVE